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*Researchers suggest assessing, diagnosing and treating the psychopathology of COVID‐19 survivors, to deepen research on inflammatory biomarkers*.

A significant number of patients who survived the COVID‐19 outbreak have presented with at least one mental health disorder, such as anxiety disorders, insomnia, mood disorders or post‐traumatic stress disorder (PTSD) at one‐month follow‐up after hospital treatment, according to a new study conducted by researchers in Milan, Italy.

The study, "Anxiety and depression in COVID‐19 survivors: Role of inflammatory and clinical predictors," was published online in July in *Brain, Behavior and Immunity*.

Researchers noted that the recent spreading of the COVID‐19 pandemic seems yet to be associated with psychiatric implications. Preliminary data suggests that patients with COVID‐19 might experience delirium, depression, anxiety and insomnia, they stated. Coronaviruses could induce psychopathological sequelae through direct viral infection of the central nervous system or indirectly via an immune response, according to the study.

"Basing on the literature on other previous coronavirus outbreaks and considering the current insight into inflammation in psychiatry, we hypothesized that COVID‐19 survivors could show a high prevalence of emergent psychiatric conditions, including mood disorders, anxiety disorders, PTSD and insomnia," Maria Gennaro Mazza, lead author who works in psychiatry and clinical psychobiology, Division of Neuroscience at the IRCCS Scientific Institute Ospedale San Raffaele, told *MHW* via email.
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Researchers screened for psychiatric symptoms 402 adults surviving COVID‐19 (265 male, mean age 58), at one‐month follow‐up after hospital treatment. A clinical interview and a battery of self‐report questionnaires were used to investigate PTSD, depression, anxiety, insomnia and obsessive‐compulsive symptomatology. They also collected sociodemographic information, clinical data, baseline inflammatory markers and follow‐up oxygen saturation levels, Mazza said.

Mazza said what makes their study stand out from previous research includes the sample size, the assessment, the measure and the population. "The assessment was based on direct clinical interviews conducted by well‐trained psychiatrists in charge using the best estimation procedure," she said.

Researchers included in the study only patients that were diagnosed with COVID‐19‐related pneumonia, excluding asymptomatic patients. "To the best of our knowledge, no other research investigates directly a so significant population exploring a wide range of psychopathological measures in COVID‐19 survivors at one‐month follow‐up," she said.
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Researchers found that in a cohort of 402 adults a significant proportion of patients self‐rated in the psychopathological range: 31% for depression, 42% for anxiety, 28% for PTSD and 40% for insomnia. Overall, 56% scored in the pathological range in at least one clinical dimension. Consistent with the known gender effect, they found that females suffered more for both anxiety and depression. Positive previous psychiatric history was also found to be associated with increased scores on most psychopathological measures.

According to the current knowledge in immunopsychiatry, researchers found that the baseline inflammation positively associated with scores of depression and anxiety. "We know that persistent low‐grade inflammation is implicated in the pathophysiology of mood disorders and associated with a lack of response to antidepressant treatment, brain abnormalities and cognitive impairment," she explained. "Our hypothesis was fully supported by our findings."

Clinical implications {#mhw32474-sec-0005}
=====================

Higher‐than‐average incidence of PTSD, major depression and anxiety, all high‐burden, noncommunicable conditions associated with years of life lived with disability, is expected in survivors, according to the study. "Moreover, depression associates with a markedly increased risk of all‐cause and cause‐specific mortality," said Mazza. "Thus, considering that there are 18 million COVID‐19 cases in the world and the number is still growing, it is of primary importance to diagnose and treat emergent psychiatric conditions, monitoring their changes over time, with the aim of reducing the disease burden."

With regard to the risk factor related to psychopathology, consistently with previous epidemiological studies, researchers have found that females, and patients with positive previous psychiatric diagnoses, suffered more in all psychopathological dimensions.

Mazza said their hypothesis was confirmed and that she and her fellow researchers were not surprised to find a high prevalence of psychopathology in females and in patients with positive psychiatric history considering the well‐known gender effect and the previous literature.

Obviously, males are most likely to die from COVID‐19, she said. "However, we think that the reason why females suffer more is to be searched in the immune‐neuro‐endocrine interactions," she said. Epidemiology shows that females develop disorders of the anxiety‐depressive sphere at higher rates of males. This greater vulnerability may also be due to the different functioning of the innate and adaptive immune system, she said. "**'Also, surprisingly, we found that outpatients showed increased anxiety and sleep disturbances and that the duration of hospitalization inversely correlated with symptomatology.'**Maria Gennaro Mazza"

"On the contrary, unexpectedly, we found no association between the severity of the clinical status and psychopathology, suggesting that psychiatric symptomatology was not a manifestation of physical symptoms," she said.

She added, "Also, surprisingly, we found that outpatients showed increased anxiety and sleep disturbances and that the duration of hospitalization inversely correlated with symptomatology. These observations suggest that less health care support could have increased the social isolation and loneliness typical of the COVID‐19 pandemic, thus inducing more psychopathology after remission."

Moreover, outpatients showed increased anxiety and sleep disturbances, while the duration of hospitalization inversely correlated with PTSD, depression, anxiety and OC symptomatology.

Researchers noted that considering the alarming impact of COVID‐19 infection on mental health, the current insights on inflammation in psychiatry and the present observation of worse inflammation leading to worse depression, they recommend to assess psychopathology of COVID‐19 survivors and to deepen research on inflammatory biomarkers, in order to diagnose and treat emergent psychiatric conditions.

"In conclusion, we think that given the context, the present results will improve our understanding of how the immune‐inflammatory response translates into psychiatric illness improving our knowledge in the etiopathogenesis of these disorders," the researchers stated.
